MET and neoplasm: Thus, developing new approaches for blocking MET kinase-mediated activity is paramount and could include targeting downstream effectors such as STMN1S16 phosphorylation to inhibit the cell cycle and tumor cell growth, in addition to more selective small molecule inhibitors or peptides for inhibiting MET, developing alternative strategies such as siRNA-based therapeutics for inhibiting HGF or MET expression, and screening for MET mutations to identify new actionable targets.